The General Hospital Corporation

Eth Zurich

Shiseido Company, Limited

Beth Israel Deaconess Medical Center, Inc.

Universitat Basel

Eth Zuerich

Universitaet Basel

Dicronis Sagl

Michael Detmar

Kentaro Kajiya

Yuzo Yoshida

Olivier Potterat

Kiichiro Yano

Jean-Christophe Leroux

Donald R Senger

Kevin Patrick Claffey

Matthias Hamburger

Adriana Sliwa-Primorac

Maria Teresa Faleschini

Antonia Elisabeth Schantl

Jihye Kim

Epameinondas Gousopoulos

Steven Proulx

Davide Brambilla

The present invention refers to lipophilic extracts of members of the Iridaceae family, such asand/or, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas. The most active components were found to be the iridals.

Promotion of lymphatic function

The present invention relates to the use of plant extracts from the genusfor the cosmetic treatment of the skin and to cosmetic preparations which comprise extracts ofand/oror other members of the genuscontaining daphnetoxin and/or other daphnane diterpenoids for skin treatment. The plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system.

Cosmetic preparations comprising Daphne extracts

This invention describes compositions comprising indocyanine green and poly(N-vinylpyrrolidone) and methods of making the same as well as applications thereof for diagnostic and therapeutic uses. One of those applications is the structural and functional assessment of the lymphatic system by fluorescence imaging.

Compositions for circulatory system visualization

The present invention relates to a method of evaluating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in a harvested skin sample, and a method of evaluating a drug for improving, preventing or treating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in cultured cells.

Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator

This application features methods of inhibiting ultraviolet B-induced skin damage in a subject. The methods include administering a VEGF-C agonist to the subject.

Use of VEGF-C agonists for inhibiting ultraviolet B-induced skin damage

Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.

Monitoring and modulating HGF/HGFR activity

This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of a subject.

Methods of reducing skin damage and edema

A method of modulating hair growth and/or hair thickness. The method includes modulating VEGF activity, e.g., modulating VEGF gene expression and/or modulating VEGF protein production and/or activity, to modulate hair growth and/or thickness. The methods can be used to either promote or inhibit hair growth or hair thickness in a subject.

Methods of modulating hair growth

The invention features a method preventing or treating long-term UVB-induced wrinkles in a subject. The method includes inhibiting angiogenesis in the skin of the subject.

Methods of preventing UVB-induced skin damage

The present invention provides a method for inhibiting tumor angiogenesis in a living subject. The method relies upon tumor angiogenesis mediated by vascular endothelial growth factor and specified induced integrin cell surface receptors expressed on the endothelial cells of tumor-included and tumor-associated blood vessels. The methodology also administers at least one antagonistic preparation effective against specified induced and expressed integrin heterodimers on the endothelial cell surface of the living subjects, the consequence of which results in an effective inhibition of tumor angiogenesis in-vivo.

Growing community of inventors

Boppelsen, Switzerland

Michael Detmar